Mayne Pharma Group Management

Management criteria checks 1/4

Mayne Pharma Group's CEO is Shawn O’Brien, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is A$2.06M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth €170.15K. The average tenure of the management team and the board of directors is 2.8 years and 2.7 years respectively.

Key information

Shawn O’Brien

Chief executive officer

AU$2.1m

Total compensation

CEO salary percentage	46.5%
CEO tenure	2.1yrs
CEO ownership	0.07%
Management average tenure	2.8yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Shawn O’Brien's remuneration changed compared to Mayne Pharma Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Compensation vs Market: Shawn's total compensation ($USD1.34M) is above average for companies of similar size in the German market ($USD782.05K).

Compensation vs Earnings: Shawn's compensation has increased whilst the company is unprofitable.

CEO

Shawn O’Brien (65 yo)

2.1yrs

Tenure

AU$2,062,194

Compensation

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 170.2k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% € 144.5k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	no data	no data
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	no data
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	no data	no data
Daniel Moore	Executive Vice President of Commercial	5.2yrs	no data	no data
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	no data	no data
Brenton Walter	Financial Controller	20.3yrs	no data	no data
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	no data	no data

2.8yrs

Average Tenure

Experienced Management: HG6's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 170.2k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% € 184.3k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% € 88.8k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% € 61.8k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% € 59.7k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% € 106.2k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	no data
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	no data

2.7yrs

Average Tenure

62yo

Average Age

Experienced Board: HG6's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Mayne Pharma Group Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

High number of new directors

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age